Navigation Links
Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
Date:9/3/2009

SAN DIEGO, Sept. 3 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Thomas Weisel Partners Healthcare Conference. The presentation is scheduled for 8:35 a.m. EDT on Wednesday, September 9, 2009, at The Four Seasons Hotel in Boston.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
2. Amira Pharmaceuticals Appoints First Vice President of Development
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
8. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to ... Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to ... drug plan (Part D) need to make changes during this period order for their ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens ... of parents report speaking with their child about sex related topics, less than 60 ... Mediaplanet is proud to announce the launch of its second edition of the “Sexual ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre ... unique properties including its unmatched natural purity of just 6 ppm TDS (Total Dissolved ... , Nothing Water has been available in several ShopRite and FoodTown stores in NJ ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, 2016, ... from eight different sites throughout Miami-Dade and Broward counties. This is the largest ... hard on Thanksgiving morning by putting together individual meals via assembly lines and ...
(Date:11/30/2016)... ... 30, 2016 , ... Northridge dentists, Dr. Assili ... for all patients. Understanding that budget can play a part in oral health ... perks, including discounts on many valuable dental treatments. Options for individuals, couples, and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
(Date:12/2/2016)... YORK , December 2, 2016 ... 5,251.11, down 1.36%; the Dow Jones Industrial Average edged 0.36% ... at 2,191.08, down 0.35%. Losses were broad based as six ... Stock-Callers.com has initiated research reports on the following Services equities: ... (NASDAQ: QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology: